PriceTargets.com logo

Bolt Biotherapeutics - BOLT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.00
  • Forecasted Upside: 366.67%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.50 As of 02/7/2023 01:00 AM ET
▼ -0.01 (-0.66%)

This chart shows the closing price for BOLT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bolt Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BOLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BOLT

Analyst Price Target is $7.00
▲ +366.67% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Bolt Biotherapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $13.00 and a low forecast of $3.00. The average price target represents a 366.67% upside from the last price of $1.50.

This chart shows the closing price for BOLT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Bolt Biotherapeutics. This rating has held steady since November 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2023Morgan StanleyLower TargetEqual Weight$5.00 ➝ $3.00Low
10/4/2022HC WainwrightInitiated CoverageBuy$8.00Low
8/11/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$8.00 ➝ $4.00Low
5/17/2022Morgan StanleyLower TargetEqual Weight$5.00High
5/13/2022Stifel NicolausLower Target$16.00 ➝ $13.00Low
1/6/2022Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
12/9/2021SVB LeerinkReiterated RatingBuyMedium
12/6/2021Stifel NicolausBoost TargetBuy$19.00 ➝ $34.00High
12/6/2021JonestradingReiterated RatingBuy$45.00High
11/24/2021JonestradingReiterated RatingBuy$45.00High
11/10/2021SVB LeerinkLower TargetOutperform$35.00 ➝ $33.00High
9/24/2021JonestradingInitiated CoverageBuy$45.00Low
8/16/2021SVB LeerinkBoost TargetOutperform$34.00 ➝ $35.00Low
5/17/2021SVB LeerinkLower TargetOutperform$37.00 ➝ $33.00Low
4/6/2021SVB LeerinkBoost TargetOutperform$36.00 ➝ $37.00Medium
3/2/2021Morgan StanleyInitiated CoverageOverweight$45.00N/A
3/2/2021SVB LeerinkInitiated CoverageOutperform$36.00N/A
3/2/2021Stifel NicolausInitiated CoverageBuy$40.00N/A
3/2/2021GuggenheimInitiated CoverageBuy$42.00N/A
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Bolt Biotherapeutics logo
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Read More

Today's Range

Now: $1.50
Low: $1.47
High: $1.55

50 Day Range

MA: $1.40
Low: $1.26
High: $1.54

52 Week Range

Now: $1.50
Low: $1.18
High: $3.64

Volume

60,604 shs

Average Volume

192,908 shs

Market Capitalization

$56.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Bolt Biotherapeutics?

The following sell-side analysts have issued research reports on Bolt Biotherapeutics in the last year: HC Wainwright, Morgan Stanley, Stifel Nicolaus, and SVB Leerink LLC.
View the latest analyst ratings for BOLT.

What is the current price target for Bolt Biotherapeutics?

4 Wall Street analysts have set twelve-month price targets for Bolt Biotherapeutics in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 366.7%. Stifel Nicolaus has the highest price target set, predicting BOLT will reach $13.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $3.00 for Bolt Biotherapeutics in the next year.
View the latest price targets for BOLT.

What is the current consensus analyst rating for Bolt Biotherapeutics?

Bolt Biotherapeutics currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BOLT, but not buy more shares or sell existing shares.
View the latest ratings for BOLT.

What other companies compete with Bolt Biotherapeutics?

Other companies that are similar to Bolt Biotherapeutics include Infinity Pharmaceuticals, Molecular Templates, Regulus Therapeutics, Fortress Biotech and Verastem. Learn More about companies similar to Bolt Biotherapeutics.

How do I contact Bolt Biotherapeutics' investor relations team?

Bolt Biotherapeutics' physical mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The company's listed phone number is 650-665-9295 and its investor relations email address is [email protected] The official website for Bolt Biotherapeutics is www.boltbio.com. Learn More about contacing Bolt Biotherapeutics investor relations.